| Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer G Arpino, C De Angelis, M Giuliano, A Giordano, C Falato, ... Oncology 77 (Suppl. 1), 23-37, 2010 | 80 | 2010 |
| Gene expression signatures and immunohistochemical subtypes add prognostic value to each other in breast cancer cohorts A Lundberg, LS Lindström, JC Harrell, C Falato, JW Carlson, PK Wright, ... Clinical Cancer Research 23 (24), 7512-7520, 2017 | 47 | 2017 |
| Ki67 measured in metastatic tissue and prognosis in patients with advanced breast cancer C Falato, J Lorent, E Tani, E Karlsson, PK Wright, J Bergh, T Foukakis Breast cancer research and treatment 147, 407-414, 2014 | 32 | 2014 |
| Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse C Falato, NP Tobin, J Lorent, LS Lindström, J Bergh, T Foukakis Molecular Oncology 10 (4), 517-525, 2016 | 25 | 2016 |
| Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer C Falato, F Schettini, T Pascual, F Brasó-Maristany, A Prat Cancer Treatment Reviews 112, 102496, 2023 | 24 | 2023 |
| Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials EM Gamper, JZ Musoro, C Coens, JJ Stelmes, C Falato, M Groenvold, ... BMC cancer 21, 1-8, 2021 | 17 | 2021 |
| A retrospective safety and efficacy analysis of the first patients treated with eribulin for metastatic breast cancer in Stockholm, Sweden L Kessler, C Falato, S Margolin, J Bergh, T Foukakis Acta Oncologica 54 (4), 527-534, 2015 | 17 | 2015 |
| Oncolytic viruses: A new immunotherapeutic approach for breast cancer treatment? JM Cejalvo, C Falato, L Villanueva, P Tolosa, X González, M Pascal, ... Cancer Treatment Reviews 106, 102392, 2022 | 12 | 2022 |
| LBA3 Patritumab deruxtecan (HER3-DXd) in early-stage HR+/HER2-breast cancer: final results of the SOLTI TOT-HER3 window of opportunity trial A Prat, C Falato, LP Brunet, OM Saez, JMC Andujar, MM Vila, P Tolosa, ... Annals of Oncology 33, S164, 2022 | 12 | 2022 |
| Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: Final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre … M Oliveira, C Falato, JM Cejalvo, MM Vila, P Tolosa, FJ Salvador-Bofill, ... Annals of Oncology 34 (8), 670-680, 2023 | 8 | 2023 |
| Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis F Schettini, O Martínez-Sáez, C Falato, I De Santo, B Conte, ... ESMO open 8 (3), 101214, 2023 | 7 | 2023 |
| A 21-gene expression assay in breast cancer T Foukakis, C Falato, J Bergh The New England journal of medicine 374 (14), 1386-1387, 2016 | 5 | 2016 |
| Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34 years longitudinal data from the Stockholm–Gotland cancer registry C Falato, SK Taylor, R Szulkin, A Nordblom, L Eriksson, A Sofiadis, ... Breast cancer research and treatment 172, 703-712, 2018 | 4 | 2018 |
| 275P Clinical and molecular impact of neoadjuvant chemotherapy (NACT) or endocrine therapy (NET) on hormone receptor positive (HR+)/HER2-negative (-) breast cancer (BC) F Schettini, F Brasó-Maristany, T Pascual, P Galván, B Conte, L Ghiglione, ... Annals of Oncology 34, S294, 2023 | 3 | 2023 |
| Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial G Villacampa, C Falato, L Paré, C Hernando, M Arumí, C Saura, G Gómez, ... European Journal of Cancer 174, 232-242, 2022 | 3 | 2022 |
| Abstract P4-10-04: Health-related quality of life (HRQoL) in hormone receptor-positive, HER2-negative, luminal B breast cancer patients treated with ribociclib plus letrozole … G Villacampa, L Paré, C Hernando, M Arumí, M Muñoz, M Gil-Gil, ... Cancer Research 82 (4_Supplement), P4-10-04-P4-10-04, 2022 | 3 | 2022 |
| Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIb–IVB mycosis fungoides/Sézary syndrome patients relapsed/refractory after a previous systemic treatment … R Stadler, PO Romero, M Bagot, P Quaglino, E Guenova, C Jonak, ... European Journal of Cancer 156, S22-S23, 2021 | 3 | 2021 |
| 124O Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive/HER2-negative (HR+/HER2-) and triple-negative breast cancer (TNBC): Results of part B of SOLTI TOT-HER3 … M Oliveira, T Pascual, PT Ortega, MM Vila, JM Cejalvo, JC Jurado, ... ESMO Open 8 (1), 2023 | 2 | 2023 |
| Abstract PD13-01: PD13-01 Elacestrant in postmenopausal women with estrogen receptor positive and HER2-negative early breast cancer: Primary efficacy and safety analysis of the … M Vidal, T Pascual, C Falato, R Sanchez-Bayona, M Muñoz, I Cerbrecos, ... Cancer Research 83 (5_Supplement), PD13-01-PD13-01, 2023 | 2 | 2023 |
| 202TiP SOLTI-1805 TOT-HER3 trial: A window-of-opportunity trial of patritumab deruxtecan (HER3-DXd) in patients with treatment-naïve, early breast cancer M Oliveira, JMC Andujar, MM Vila, PT Ortega, OM Saez, FJS Bofill, ... Annals of Oncology 33, S628, 2022 | 2 | 2022 |
